We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Another study — the largest to date — has shown that anti-malaria drugs hydroxychloroquine and chloroquine have no benefit in treating COVID-19, in fact have a negative effect on patient survival and are associated with an increase in ventricular arrhythmias. Read More
NIH Friday confirmed preliminary remdesivir trial data showing that the drug delivered a median recovery time of 11 days compared with 15 on placebo, establishing it as the standard of care for patients with moderate to severe disease. Read More
A leading COVID-19 vaccine candidate has shown promise as being safe and effective in humans and produced an immune response against the coronavirus, according to preliminary data from a phase 1 trial of 108 healthy adults in China. Read More
Enrollment for a large, global trial of chloroquine and hydroxychloroquine for the prevention of COVID-19 is getting under way in the United Kingdom. Read More
AstraZeneca has nabbed an HHS contract worth up to $1.2 billion to speed development and production of the University of Oxford’s promising COVID-19 vaccine candidate. The deal also would lock in the distribution of 300 million doses of the vaccine for the U.S. Read More